MYAIRVO 3 (High Flow Nasal Therapy; HFNT) For COPD Patients in the Home – A Multi-Center, Randomized Control Trial
HiFlo COPD Research Group provide a breakdown of their clinical trial to determine if HFNT delivered by myAirvo 3 increases the time to first moderate exacerbation or severe exacerbation or all-cause mortality in patients with moderate to severe COPD.